Verrica Pharmaceuticals Inc. balance sheet

At the end of fiscal 2025, Verrica Pharmaceuticals Inc. had total assets of $47.1m, total liabilities of $22.4m and shareholders' equity of $24.7m. It held $30.1m in cash against $0 of debt: net cash of $30.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Verrica Pharmaceuticals Inc.: balance sheet, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	16	34	70	46	30	11
Receivables	—	0	4	0	5	11
Inventory	—	0	1	2	2	3
Total current assets	74	39	78	51	43	33
Total assets	80	45	82	54	47	36
Accounts payable	1	1	2	2	2	2
Deferred revenue (current)	—	—	—	0	1	1
Total current liabilities	46	3	17	29	16	22
Short-term debt	42	0	0	13	0	—
Long-term debt	—	0	43	31	0	—
Total debt	42	0	43	31	0	0
Total liabilities	48	5	62	64	22	32
Shareholders' equity	33	40	20	−10	25	4
Net debt (negative = net cash)	26	−34	−27	−15	−30	−11
Shares outstanding	—	—	—	9m	—	17m

US$ millions unless shown otherwise. Fiscal quarters.

Verrica Pharmaceuticals Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	0	0	6	9	7	5	8	11
Inventory	3	2	2	3	2	2	2	3
Total current assets	28	51	39	37	36	43	34	33
Total assets	33	54	42	39	41	47	39	36
Accounts payable	1	2	1	2	2	2	2	2
Deferred revenue (current)	—	0	—	0	2	1	1	1
Total current liabilities	21	29	29	29	29	16	16	22
Short-term debt	—	13	13	13	12	0	—	—
Long-term debt	43	31	28	25	22	0	—	—
Total debt	43	44	41	37	34	0	—	—
Total liabilities	67	64	61	57	58	22	23	32
Shareholders' equity	−34	−10	−19	−17	−17	25	16	4
Shares outstanding	46m	9m	92m	9m	9m	17m	17m	17m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: SCLX vs VRCA JAGX vs VRCA SBFM vs VRCA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Verrica Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verrica Pharmaceuticals Inc.